Mostrar el registro sencillo

dc.contributor.authorLago, Santiago G.
dc.contributor.authorTomasik, Jakub
dc.contributor.authorRees, Geertje F. van
dc.contributor.authorRamsey, Jordan M.
dc.contributor.authorCooper, Jason D.
dc.contributor.authorBroek, Jantine A.
dc.contributor.authorSuárez Pinilla, Paula 
dc.contributor.authorRuland, Tillmann
dc.contributor.authorAuyeug, Bonnie
dc.contributor.authorMikova, Olya
dc.contributor.authorKabacs, Nikolett
dc.contributor.authorArolt, Volker
dc.contributor.authorBaron-Cohen, Simon
dc.contributor.authorCrespo Facorro, Benedicto 
dc.contributor.authorBahn, Sabine
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2024-02-09T14:37:46Z
dc.date.available2024-02-09T14:37:46Z
dc.date.issued2020
dc.identifier.issn1359-4184
dc.identifier.issn1476-5578
dc.identifier.urihttps://hdl.handle.net/10902/31631
dc.description.abstractNeuropsychiatric disorders overlap in symptoms and share genetic risk factors, challenging their current classification into distinct diagnostic categories. Novel cross-disorder approaches are needed to improve our understanding of the heterogeneous nature of neuropsychiatric diseases and overcome existing bottlenecks in their diagnosis and treatment. Here we employ high-content multi-parameter phospho-specific flow cytometry, fluorescent cell barcoding and automated sample preparation to characterize ex vivo signaling network responses (n?=?1764) measured at the single-cell level in B and T lymphocytes across patients diagnosed with four major neuropsychiatric disorders: autism spectrum condition (ASC), bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ; n?=?25 each), alongside matched healthy controls (n?=?100). We identified 25 nodes (individual cell subtype?epitope?ligand combinations) significantly altered relative to the control group, with variable overlap between different neuropsychiatric diseases and heterogeneously expressed at the level of each individual patient. Reconstruction of the diagnostic categories from the altered nodes revealed an overlapping neuropsychiatric spectrum extending from MDD on one end, through BD and SCZ, to ASC on the other end. Network analysis showed that although the pathway structure of the epitopes was broadly preserved across the clinical groups, there were multiple discrete alterations in network connectivity, such as disconnections within the antigen/integrin receptor pathway and increased negative regulation within the Akt1 pathway in CD4+ T cells from ASC and SCZ patients, in addition to increased correlation of Stat1 (pY701) and Stat5 (pY694) responses in B cells from BD and MDD patients. Our results support the ?dimensional? approach to neuropsychiatric disease classification and suggest potential novel drug targets along the neuropsychiatric spectrum.es_ES
dc.description.sponsorshipWe would like to thank clinicians and support staff at the affiliated institutions for patient recruitment and sample collection, including Liliana Ruta and Stephanie Mok for the ASC cohort; Eva Brombacher for sample preparation; collaborators Joshua A. Bishop, Tracey Petryshen, and Steven J. Haggarty from Harvard Medical School (Boston, MA, USA) for contribution of the JB1121 compound; and PBMC donors for provision of biological samples. This work was supported by grants to S.B. from the Stanley Medical Research Institute (SMRI) and the Engineering and Physical Sciences Research Council UK (EPSRC CASE studentship and Impact Acceleration Award). S.G.L. was supported an by EPSRC CASE studentship and Psynova Neurotech Ltd. J.T. was supported through grants awarded t`o Psynova Neurotech Ltd. by the European Union FP7 funding scheme: Marie Curie Actions Industry-Academia Partnerships and Pathways (ref. 286334, PSYCH-AID project); by the Virgo consortium, funded by the Dutch Government (ref. FES0908); by the Netherlands Genomics Initiative (ref. 050-060); and by the S. G. Lago et al. Dutch Fund for Economic Structure Reinforcement, the NeuroBasic PharmaPhenomics project (ref. 0908). S.B.-C. and B.A. were supported by the Autism Research Trust.es_ES
dc.format.extent18 p.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Groupes_ES
dc.rightsAttribution 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceMolecular Psychiatry, 2020, 25(10), 2355-2372es_ES
dc.titleExploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networkses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1038/s41380-018-0123-4es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1038/s41380-018-0123-4
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution 4.0 International